152 related articles for article (PubMed ID: 21605644)
21. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
[TBL] [Abstract][Full Text] [Related]
22. Immunization aginast tetanus with aluminium free-versus aluminium contain triple vaccine.
Ullberg-Olsson K; Wickbom B; Eriksson E
Dev Biol Stand; 1979; 43():39-41. PubMed ID: 520684
[TBL] [Abstract][Full Text] [Related]
23. Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines--I.
Aggerbeck H; Heron I
Vaccine; 1995 Oct; 13(14):1360-5. PubMed ID: 8585294
[TBL] [Abstract][Full Text] [Related]
24. Preformulation characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae.
Iyer V; Hu L; Liyanage MR; Esfandiary R; Reinisch C; Meinke A; Maisonneuve J; Volkin DB; Joshi SB; Middaugh CR
J Pharm Sci; 2012 Sep; 101(9):3078-90. PubMed ID: 22538529
[TBL] [Abstract][Full Text] [Related]
25. Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine.
Schwendeman SP; Costantino HR; Gupta RK; Tobio M; Chang AC; Alonso MJ; Siber GR; Langer R
Dev Biol Stand; 1996; 87():293-306. PubMed ID: 8854030
[TBL] [Abstract][Full Text] [Related]
26. Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology.
Baxendale A; van Hooff P; Durrant LG; Spendlove I; Howdle SM; Woods HM; Whitaker MJ; Davies OR; Naylor A; Lewis AL; Illum L
Int J Pharm; 2011 Jul; 413(1-2):147-54. PubMed ID: 21554938
[TBL] [Abstract][Full Text] [Related]
27. A predictive equation for the primary immune response of mice to adsorbed tetanus toxoid as a function of dose of antigen and dose of adjuvant.
Levine L
J Immunol; 1972 Nov; 109(5):1338-42. PubMed ID: 5079094
[No Abstract] [Full Text] [Related]
28. Immunization against neonatal tetanus in New Guinea.
Hardegree MC; Barile MF; Pittman M; Schofield FD; Maclennan R; Kelly A
Bull World Health Organ; 1970; 43(3):439-51. PubMed ID: 5312998
[TBL] [Abstract][Full Text] [Related]
29. Studies on adjuvants for human prophylactics. II. Influence of the route of injection on the activity of adjuvants to tetanus toxoid in guinea pigs.
Yamamoto A; Murata R
Jpn J Med Sci Biol; 1978; 31(5-6):393-406. PubMed ID: 156804
[TBL] [Abstract][Full Text] [Related]
30. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.
Hansen B; Sokolovska A; HogenEsch H; Hem SL
Vaccine; 2007 Sep; 25(36):6618-24. PubMed ID: 17681647
[TBL] [Abstract][Full Text] [Related]
31. On the effect of Al(OH)3 as an immunological adjuvant.
Majgaard Jensen O; Koch C
APMIS; 1988 Mar; 96(3):257-64. PubMed ID: 3348913
[TBL] [Abstract][Full Text] [Related]
32. [A new method of preparation of rabies antiserum using tetanus toxoid and aluminum gel as adjuvants].
Oropeza RM; García y Pérez G; Calderón Manes S
Rev Invest Salud Publica; 1972; 32(3-4):195-9. PubMed ID: 4670623
[No Abstract] [Full Text] [Related]
33. Secondary response to boostering by purified aluminium-hydroxide-adsorbed tetanus anatoxin in aging and in aged adults.
Solomonova K; Vizev S
Immunobiology; 1981; 158(4):312-9. PubMed ID: 7239554
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of Antigen Adsorption Onto an Aluminum-Hydroxide Adjuvant Evaluated by High-Throughput Screening.
Jully V; Mathot F; Moniotte N; Préat V; Lemoine D
J Pharm Sci; 2016 Jun; 105(6):1829-1836. PubMed ID: 27238481
[TBL] [Abstract][Full Text] [Related]
35. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity.
Carra JH; Wannemacher RW; Tammariello RF; Lindsey CY; Dinterman RE; Schokman RD; Smith LA
Vaccine; 2007 May; 25(21):4149-58. PubMed ID: 17408819
[TBL] [Abstract][Full Text] [Related]
36. Enhanced expression of soluble recombinant tetanus neurotoxin Hc in Escherichia coli as a tetanus vaccine candidate.
Yu R; Hou L; Yu C; Liu S; Ren J; Fang T; Zhang X; Chen W
Immunobiology; 2011 Apr; 216(4):485-90. PubMed ID: 20888666
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production.
Iyer S; HogenEsch H; Hem SL
Vaccine; 2003 Mar; 21(11-12):1219-23. PubMed ID: 12559801
[TBL] [Abstract][Full Text] [Related]
38. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties.
Goto N; Kato H; Maeyama J; Shibano M; Saito T; Yamaguchi J; Yoshihara S
Vaccine; 1997; 15(12-13):1364-71. PubMed ID: 9302746
[TBL] [Abstract][Full Text] [Related]
39. Micro/nanoparticle adjuvants: preparation and formulation with antigens.
Malyala P; Singh M
Methods Mol Biol; 2010; 626():91-101. PubMed ID: 20099123
[TBL] [Abstract][Full Text] [Related]
40. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
